PBE: Biotech Could Be Next Big Winner

seekingalpha04-01

Biotechnology and genomics sector has not performed well in recent years, making it an attractive investment opportunity.The Invesco Biotechnology & Genome ETF offers comprehensive exposure to the ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2424169741?lang=en_US&edition=fundamental","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1453942652/image_1453942652.jpg","is_english":true,"pubTime":"2024-04-01 22:30","share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","id":"2424169741","market":"sg","top_or_hot":-1,"title":"PBE: Biotech Could Be Next Big Winner","media":"seekingalpha","content":"<div>\n<p>Biotechnology and genomics sector has not performed well in recent years, making it an attractive investment opportunity.The Invesco Biotechnology & Genome ETF offers comprehensive exposure to the ...</p>\n\n<a href=\"https://seekingalpha.com/article/4681465-pbe-biotech-could-be-next-big-winner\">Source Link</a>\n\n</div>\n","source":"seekingalpha","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>PBE: Biotech Could Be Next Big Winner</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPBE: Biotech Could Be Next Big Winner\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-04-01 22:30 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/article/4681465-pbe-biotech-could-be-next-big-winner><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Biotechnology and genomics sector has not performed well in recent years, making it an attractive investment opportunity.The Invesco Biotechnology & Genome ETF offers comprehensive exposure to the ...</p>\n\n<a href=\"https://seekingalpha.com/article/4681465-pbe-biotech-could-be-next-big-winner\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE0002270589.USD","symbol_name":"LEGG MASON CLEARBRIDGE VALUE \"A\" (USD) INC","start_time":0,"source_url":"https://seekingalpha.com/article/4681465-pbe-biotech-could-be-next-big-winner","article_id":"2424169741","we_media_id":null,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1453942652/image_1453942652.jpg"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2424169741","pubTimestamp":1711981800,"sourceInfo":{"source_id":"seekingalpha","name":"Seeking Alpha"},"weMediaInfo":null,"summary":"Biotechnology and genomics sector has not performed well in recent years, making it an attractive investment opportunity.The Invesco Biotechnology & Genome ETF offers comprehensive exposure to the biotech sector with a diversified portfolio.PBE has performed better than some similar ETFs but worse than others, highlighting the importance of stock selection in this sector.anusorn nakdee Investing in the field of biotechnology and genomics can be a profitable venture, especially for investors keen on scientific and technological advancements. The problem?","collect":0,"end_time":0,"defaultTopTitle":"seekingalpha.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"IE0002270589.USD":"LEGG MASON CLEARBRIDGE VALUE \"A\" (USD) INC","LU0061475181.USD":"THREADNEEDLE (LUX) AMERICAN \"AU\" (USD) ACC","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","BK4588":"碎股","BK4550":"红杉资本持仓","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","LU0256863811.USD":"ALLIANZ US EQUITY \"A\" INC","LU2362541273.HKD":"WELLINGTON NEXT GENERATION GLOBAL EQUITY \"A\" (HKD) ACC","LU1585245621.USD":"EASTSPRING INV GLOBAL LOW VOLATILITY EQUITY FUND \"A\" (USD) ACC B","VRTX":"福泰制药","LU2362541513.USD":"WELLINGTON NEXT GENERATION GLOBAL EQUITY \"A\" (USD) ACC","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","BK4566":"资本集团","XBI":"SPDR S&P Biotech ETF","BIIB":"渤健公司","IE00B7SZLL34.SGD":"Legg Mason ClearBridge - Value A Acc SGD-H","BK4581":"高盛持仓","LU2065171311.SGD":"M&G (LUX) GLOBAL MAXIMA \"A\" (SGD) ACC","LU0234570918.USD":"高盛全球核心股票组合Acc Close","IE00B894F039.SGD":"Legg Mason ClearBridge - US Aggressive Growth A Acc SGD-H","LU0417517546.SGD":"Allianz US Equity Cl AT Acc SGD","LU2065171402.SGD":"M&G (LUX) GLOBAL MAXIMA \"A\" (SGD) INC","IE00B19Z3581.USD":"Legg Mason ClearBridge - Value A Acc USD","LU0079474960.USD":"联博美国增长基金A","PBE":"INVESCO BIOTECHNOLOGY & GENOME ETF","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","IE00B19Z3B42.SGD":"Legg Mason ClearBridge - Value A Acc SGD","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","FDN":"First Trust Dow Jones Internet I","IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","BK4532":"文艺复兴科技持仓","BMRN":"拜玛林制药","LU1430594728.SGD":"Eastspring Investments - Global Low Volatility Equity AS SGD","LU2065170008.USD":"M&G (LUX) GLOBAL MAXIMA \"A\" (USD) INC","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","IE00B19Z9P08.USD":"LEGG MASON CLEARBRIDGE US AGGRESSIVE GROWTH \"A\" (USD) INC","LU2362540622.SGD":"WELLINGTON NEXT GENERATION GLOBAL EQUITY \"A\" (SGDHDG) ACC","BK4585":"ETF&股票定投概念","BK4567":"ESG概念","LU0058720904.USD":"联博国际健康护理基金A","NBIX":"神经分泌生物科学","BK4139":"生物科技","BK4533":"AQR资本管理(全球第二大对冲基金)","IE00B19Z9Z06.USD":"Legg Mason ClearBridge - US Aggressive Growth A Acc USD","IBB":"生物科技指数ETF-iShares Nasdaq","LU2065169927.USD":"M&G (LUX) GLOBAL MAXIMA \"A\" (USD) ACC"},"translate_title":"PBE：生物技术可能是下一个大赢家","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"XBI":1,"VRTX":1,"PBE":1,"NBIX":1,"BIIB":1,"BMRN":1,"IBB":1,"FDN":0.9},"content_text":"Biotechnology and genomics sector has not performed well in recent years, making it an attractive investment opportunity.The Invesco Biotechnology & Genome ETF offers comprehensive exposure to the biotech sector with a diversified portfolio.PBE has performed better than some similar ETFs but worse than others, highlighting the importance of stock selection in this sector.anusorn nakdee Investing in the field of biotechnology and genomics can be a profitable venture, especially for investors keen on scientific and technological advancements. The problem? It hasn't done well at all in the last couple of years. As a matter of fact, when looking at the entire sector, you'd be hard pressed to call it a bull market. That may be exactly why you want to consider it right now - the fact that it lagged so badly against broad market averages. stockcharts.com If you agree with that and are bullish on the space, the Invesco Biotechnology & Genome ETF (NYSEARCA:PBE) might be the fund for you. PBE operates as a passive exchange-traded fund, and has been around since 2005. Its primary objective is to give investors comprehensive exposure to the Biotech sector within the healthcare sector, seeking to mimic the returns of the Dynamic Biotechnology & Genome Intellidex Index, accounting for operational costs and expenses. PBE's assets under management currently exceed $245 million. The fund maintains a total expense ratio of 0.58%, aligning it with the average cost structure among comparable funds in this investment category. Top ETF Holdings PBE's portfolio is diversified across 32 US biotechnology and genome companies. These are firms primarily engaged in the research, development, manufacture, and distribution of various biotechnological products, services, and processes. Holdings include:  Vertex Pharmaceuticals Incorporated (VRTX): As a pioneer in the biotechnology industry, Vertex is dedicated to advancing scientific research to forge revolutionary treatments for individuals grappling with grave health conditions. Neurocrine Biosciences, Inc. (NBIX): Neurocrine Biosciences is at the forefront of biopharmaceutical innovation, focusing its research and development efforts on addressing the pressing needs of patients suffering from diseases that currently lack sufficient treatment options. Biogen Incorporated (BIIB): With roots in the biotech hub of Cambridge, Massachusetts, Biogen is a global leader in biotechnology, committed to the discovery and refinement of treatments that can significantly improve the lives of those affected by neurological disorders across the globe. BioMarin Pharmaceutical Incorporated (BMRN): Specializing in the field of biotechnology, BioMarin Pharmaceutical is dedicated to the development and commercialization of breakthrough therapeutic solutions for individuals facing severe and life-altering rare disorders.  Sector Composition and Weightings The fund's portfolio is heavily allocated to the Healthcare sector as expected, accounting for 100% of its holdings. The sector distribution is as follows:  Biotechnology: 78.17% Life Sciences Tools & Services: 11.34% Pharmaceuticals: 5.66% Health Care Services: 4.82%  Peer Comparison PBE competes with other similar ETFs like the SPDR S&P Biotech ETF (XBI) and the iShares Biotechnology ETF (IBB). XBI tracks the S&P Biotechnology Select Industry Index. On the other hand, IBB tracks the Nasdaq Biotechnology Index. PBE has performed better than XBI but worse than IBB. Much of this has to do with IBB's weighting in Amgen and Gilead, which make up 8.39% and 8.21% respectively. PBE doesn't have those two stocks in the top holdings, and those stocks have performed well. stockcharts.com Pros and Cons of Investing in Biotechnology and Genomics Theme Investing in biotechnology and genomics comes with its own set of advantages and disadvantages. On the positive side, this sector offers significant growth potential due to the constant advancements in scientific and technological research. Investing in PBE allows investors to gain diversified exposure to a broad group of companies in the biotechnology sector, thereby minimizing single stock risk. On the downside, the sector is susceptible to market volatility and regulatory risks. In addition, the fund's performance is dependent on the success of the research and development efforts of the companies it invests in, which can be uncertain and costly. Conclusion: To Invest or Not to Invest  Investing in PBE could be an attractive option for those who are bullish about the future of biotechnology and genomics. However, potential investors should be aware of the risks associated with this sector, including high volatility and regulatory uncertainties. I think it's a good fund that provides good representation of Biotech companies which have largely been left in the dust over the last several years. I suspect this will change and Biotech could be a big winner in the future. If I'm right, this is a good proxy to play it.","kind":null,"is_publish_news":null,"is_publish_highlight":null,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2424169741"}